Market closed
Apogee Therapeutics/$APGE
Apogee Therapeutics shares are trading higher after analysts indicated a potential 134% upside in the stock, supported by strong agreement in raising earnings estimates.
10 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Apogee Therapeutics
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Ticker
$APGE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
196
Website
APGE Metrics
BasicAdvanced
$2B
-
-$3.30
-
-
Price and volume
Market cap
$2B
52-week high
$50.56
52-week low
$26.20
Average daily volume
688K
Financial strength
Current ratio
18.547
Quick ratio
18.23
Long term debt to equity
1.199
Total debt to equity
1.651
Management effectiveness
Return on assets (TTM)
-23.46%
Return on equity (TTM)
-33.22%
Valuation
Price to book
2.85
Price to tangible book (TTM)
2.85
Price to free cash flow (TTM)
-11.287
Growth
Earnings per share change (TTM)
-1.74%
APGE News
AllArticlesVideos
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference
GlobeNewsWire·1 week ago
Apogee Therapeutics: Engineering Biologic Dominance
Seeking Alpha·4 weeks ago
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial
Benzinga·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Apogee Therapeutics stock?
Apogee Therapeutics (APGE) has a market cap of $2B as of May 09, 2025.
What is the P/E ratio for Apogee Therapeutics stock?
The price to earnings (P/E) ratio for Apogee Therapeutics (APGE) stock is 0 as of May 09, 2025.
Does Apogee Therapeutics stock pay dividends?
No, Apogee Therapeutics (APGE) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next Apogee Therapeutics dividend payment date?
Apogee Therapeutics (APGE) stock does not pay dividends to its shareholders.
What is the beta indicator for Apogee Therapeutics?
Apogee Therapeutics (APGE) does not currently have a Beta indicator.